Institut Curie has recently announced the successful acquisition of Emglev Therapeutics by Valour Bio, a subsidiary of Valerio Therapeutics. This acquisition occurred approximately one year after Emglev's establishment, which highlights the company's focus on developing next-generation antibodies for solid tumor treatment.

The success of this acquisition demonstrates the effectiveness of Institut Curie's incubation program in fostering innovative technologies for the benefit of patients.

Additionally, Institut Curie has launched Spotlight Medical, a new start-up dedicated to optimizing personalized cancer treatments, and introduced Cereus Biosciences, a start-up focused on cancer vaccine development. These initiatives reflect Institut Curie's commitment to advancing cancer research and treatment through collaborations and technology transfer.